Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Delcath Systems (DCTH) stock in plain English

Free brief · no signupStart here
DCTHPublished Nov 15, 2026
Delcath Systems Inc
Healthcare · Medical Devices
Sells targeted liver cancer treatment systems combining chemotherapy drugs with specialized blood filtration kits.
Assets:
HEPZATO KITFDA-approved liver-directed therapy for metastatic uveal melanoma
CHEMOSAT platformCommercial medical device marketed in European cancer centers
Queensbury facilityManufacturing and packaging hub located in New York
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

76
OPS ScoreOperating finances
Latest quote
-2.34%$19.24
$669.32M
124.2×
$109.90M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was DCTH. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Delcath Systems (DCTH) do?

Delcath Systems Inc (DCTH) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells targeted liver cancer treatment systems combining chemotherapy drugs with specialized blood filtration kits. Delivers high-dose chemotherapy directly to the liver while filtering it out of the general bloodstream. It is worth $669.32M on the market and sold $109.90M over the last year.

Market cap
$669.32M
P/E ratio
124.2×
Annual sales
$109.90M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 15, 2026

Brands and businesses behind DCTH

  • HEPZATO: It generates revenue by selling liver delivery kits to authorized treatment centers for adult cancer patients.
  • CHEMOSAT: It earns money through medical device sales for targeted hepatic chemosaturation procedures across European hospitals.

DCTH’s flags, in plain English

Each flag is a number from Delcath Systems’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Stupid Cash

Can pay this year's bills 10.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 2% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 87.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Priced for Perfection

Priced at 124.2 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about DCTH

How big is Delcath Systems?

Delcath Systems’ market cap is $669.32M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $109.90M: what customers paid the company over the last year, before any costs.

What is DCTH’s P/E ratio?

DCTH’s P/E ratio is 124.2×. Investors pay about 124.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with DCTH?

The business depends almost entirely on the commercial adoption of its single proprietary liver treatment platform. That is one risk on Delcath Systems’ card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Delcath Systems’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. DCTH’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card